Comparison of the clinical efficacy and safety of pantoprazole vs ranitidine over three years to prevent relapse in patients with healed erosive esophagitis

@article{Richter2003ComparisonOT,
  title={Comparison of the clinical efficacy and safety of pantoprazole vs ranitidine over three years to prevent relapse in patients with healed erosive esophagitis},
  author={J. Richter and P. Fraga and M. Mack and Andrew Dermovsesian and S. Nielsen and W. Bochenek and W. Weinstein},
  journal={Gastroenterology},
  year={2003},
  volume={124}
}
3 Citations

Topics from this paper

Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions.
TLDR
No clear evidence that the long-term use of PPIs can cause or accelerate the progression of corpus gastric atrophy or intestinal metaplasia is found, and people with PPI maintenance treatment may have a higher possibility of experiencing either diffuse or linear/micronodular (focal) ECL cell hyperplasia. Expand
Meta-analyses: does long-term PPI use increase the risk of gastric premalignant lesions?
TLDR
Maintenance PPIs did not have an association with increased gastric atrophic changes or ECL-cell hyperplasia for at least three years in RCTs, according to a systematic review of the available literature. Expand
Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease.
TLDR
The findings in this review support the long-term treatment of oesophagitis to prevent relapse, both endoscopically and symptomatically, as well as demonstrating a role for PPI-intolerant patients. Expand